Overview

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The INTEGA study assesses therapy Options for advanced or metastatic esophagogastric Adenocarcinoma in patients overexpressing human epidermal receptor type 2 (HER2 positive patients). Current treatment options in this situation include chemotherapy based palliative treatment in combination withTrastuzumab. Recent studies have shown that immunotherapy with Nivolumab or Ipilimumab after previous chemotherapy can also improve survival in esophagogastric cancer. This study assesses the efficacy of two experimental first line treatment strategies: A) Chemo-free immunotherapy with Trastuzumab, Nivolumab and Ipilimumab and B) addition of Nivolumab to the standard regimen (FOLFOX chemotherapy and Trastuzumab).

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab
Trastuzumab